UCB: sells rights to erectile disfunction drug
(CercleFinance.com) - Belgian pharmaceutical group UCB has agreed to sell the rights to its drug Alprostadil for the treatment of erectile disfunction to British specialty pharmaceutical firm Advanz Pharma for 75 million euros.
On Friday Advanz said that it has signed a definitive agreement to acquire the rights to a portfolio of Alprostadil products in 10 EU countries, as well as the UK, Russia, Ukraine and Brazil, from UCB.
The portfolio consists of two niche, injectable products for the treatment of erectile disfunction and peripheral arterial occlusive disease, the drugmaker said.
All Alprostadil brands generated approximately 33 million dollars in revenue in 2019 in the markets where Advanz will hold the rights.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
On Friday Advanz said that it has signed a definitive agreement to acquire the rights to a portfolio of Alprostadil products in 10 EU countries, as well as the UK, Russia, Ukraine and Brazil, from UCB.
The portfolio consists of two niche, injectable products for the treatment of erectile disfunction and peripheral arterial occlusive disease, the drugmaker said.
All Alprostadil brands generated approximately 33 million dollars in revenue in 2019 in the markets where Advanz will hold the rights.
Copyright (c) 2020 CercleFinance.com. All rights reserved.